Harel Insurance Investments & Financial Services Ltd. Has $5.28 Million Holdings in Cencora, Inc. $COR

Harel Insurance Investments & Financial Services Ltd. cut its holdings in Cencora, Inc. (NYSE:COR) by 11.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,911 shares of the company’s stock after selling 2,105 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Cencora were worth $5,278,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in COR. Norges Bank bought a new position in shares of Cencora in the second quarter worth about $695,215,000. Artisan Partners Limited Partnership bought a new stake in shares of Cencora during the second quarter valued at approximately $411,888,000. Vanguard Group Inc. increased its holdings in shares of Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares in the last quarter. Viking Global Investors LP raised its position in Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in Cencora by 228.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock worth $292,207,000 after purchasing an additional 677,952 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $343.45, for a total value of $1,750,221.20. Following the completion of the sale, the chief executive officer directly owned 68,059 shares in the company, valued at $23,374,863.55. This represents a 6.97% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 20,317 shares of company stock valued at $7,009,260. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Performance

COR stock opened at $354.96 on Friday. Cencora, Inc. has a 1-year low of $237.71 and a 1-year high of $377.54. The business’s 50-day moving average price is $349.64 and its two-hundred day moving average price is $320.12. The firm has a market cap of $68.86 billion, a PE ratio of 44.65, a P/E/G ratio of 1.69 and a beta of 0.66. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.Cencora’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 30.19%.

Analysts Set New Price Targets

COR has been the topic of a number of recent research reports. Bank of America decreased their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. UBS Group boosted their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Robert W. Baird set a $415.00 target price on shares of Cencora in a research report on Tuesday. Finally, TD Cowen lifted their price target on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $381.42.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.